NCT05902598View on ClinicalTrials.gov

A Phase 3 Study of VSA001 in Chinese Adults with Familial Chylomicronemia Syndrome

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

January 15, 2025

Study Completion Date

July 31, 2026

Conditions
Familial Chylomicronemia Syndrome
Interventions
DRUG

VSA001 injection

also referred to as ARO-APOC3

DRUG

Placebo

Matching VSA001 injection

Trial Locations (1)

Unknown

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Visirna Therapeutics HK Limited

INDUSTRY